A Comparison of Oral Milrinone, Digoxin, and Their Combination in the Treatment of Patients with Chronic Heart Failure

New England Journal of Medicine

Volumn 320, Issue 11, 1989, Pages 677-683

  Dibianco, Robert ^a   Shabetai, Ralph ^a   Kostuk, William ^a   Moran, John ^a   Schlant, Robert C ^a   Wright, Richard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; MILRINONE;

CONTROLLED STUDY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0024511994     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198903163201101     Document Type: Article

References (51)

1. Braunwald E. Heart failure; evaluation of therapy based on a consideration of natural history. In: Braunwald E, Sonnenblick EH, Chakrin LW, Schwartz RP Jr. eds. Milrinone: investigation of new inotropic therapy for congestive heart failure. New York: Raven Press, 1984:1–13.
2. Cohn JN, ed. Drug treatment of heart failure. New York: Yorke Medical Books, 1983:1–12.
3. Marsh JD, Smith TW. Clinical use of cardiac glycosides in congestive heart failure. In: Smith TW, ed. Digitalis glycosides. Orlando, Fia.: Grune & Stratton, 1986:83–113.
4. Lewis RP. Digitalis. In: Leier CV, ed. Cardiotonic drugs: a clinical survey. New York: Marcel Dekker, 1986:85–150.
5. Mulrow CD, Feussner JR, Velez R. Reevaluation of digitalis efficacy: new light on an old leaf. Ann Intern Med 1984; 101: 113–7.
6. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis — a new controversy regarding an old drug: the pitfalls of inappropriate methods. Circulation 1986; 73: 14–8.
7. Fleg JL, Gottlieb SH, Lakatta EG. Is digoxin really important in treatment of compensated heart failure? A placebo-controlled crossover study in patients with sinus rhythm. Am J Med 1982; 73: 244–50.
8. Marsh JD, Smith TW. Epidemiology and general considerations of digitalis toxicity. In: Smith TW, ed. Digitalis glycosides. Orlando, Fia.: Grune & Stratton, 1986:217–25.
9. Smith TW. Digitalis: mechanisms of action and clinical use. N Engl J Med 1988; 318: 358–65.
10. Moss AJ. Davis HT, Conard DL, DeCamilla JJ, Odoroff CL. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981; 64: 1150–6.
11. Bigger JT Jr, Fleiss JL, Rolnitsky LM, Merab JP, Ferrick KJ. Effect of digitalis treatment on survival after acute myocardial infarction. Am J Cardiol 1985; 55: 623–30.
12. Alousi AA, Stankus GP, Stuart JC, Walton LH. Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species. J Cardiovasc Pharmacol 1983; 5: 804–11.
13. Alousi AA, Canter JM, Montenaro MJ, Fort DJ, Ferrari RA. Cardiotonic activity of milrinone, a new and potent cardiac bipyridine, on the normal and failing heart of experimental animals. J Cardiovasc Pharmacol 1983; 5: 792–803.
14. Jaski BE, Fifer MA, Wright RF, Braunwald E, Colucci WS. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. J Clin Invest 1985; 75: 643–9.
15. Borow KM, Come PC, Neumann A, Baim DS, Braunwald E, Grossman W. Physiologic assessment of the inotropic, vasodilator and afterload reducing effects of milrinone in subjects without cardiac disease. Am J Cardiol 1985; 55: 1204–9.
16. Ludmer PL, Wright RF, Arnold JM, Ganz P, Braunwald E, Colucci WS. Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique. Circulation 1986; 73: 130–7.
17. Timmis AD, Smyth P, Monaghan M, et al. Milrinone in heart failure: acute effects on left ventricular systolic function and myocardial metabolism. Br Heart J 1985; 54: 36–41.
18. Monrad ES, McKay RG, Baim DS, et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 1984; 70: 1030–7.
19. Cody RJ, Muller FB, Kubo SH, Rutman H, Leonard D. Identification of the direct vasodilator effect of milrinone with an isolated limb preparation in patients with chronic congestive heart failure. Circulation 1986; 73: 124–9.
20. Earl CQ, Linden J, Weglicki WB. Biochemical mechanisms for the inotropic effect of the cardiotonic drug milrinone. J Cardiovasc Pharmacol 1986; 8: 864–72.
21. Olson EM, Kim D, Smith TW, Marsh JD. Mechanism of the positive inotropic effect of milrinone in cultured embryonic chick ventricular cells. J Mol Cell Cardiol 1987; 19: 95–104.
22. Mylotte KM, Cody V, Davis PJ, Davis FB, Bias SD, Schoenl M. Milrinone and thyroid hormone stimulate myocardial membrane Ca2+-ATPase activity and share structural homologies. Proc Natl Acad Sci USA 1985; 82: 7974–8.
23. Baim DS, McDowell AV, Cherniles J, et al. Evaluation of a new bipyridine inotropic agent — milrinone — in patients with severe congestive heart failure. N Engl J Med 1983; 309: 748–56.
24. Maskin CS, Sinoway L, Chadwick B, Sonnenblick EH, LeJemtel TH. Sustained hemodynamic and clinical effects of a new cardiotonic agent, WIN 47203. in patients with severe congestive heart failure. Circulation 1983; 67: 1065–70.
25. Sinoway LS, Maskin CS, Chadwick B, Forman R, Sonnenblick EH, LeJemtel TH. Long-term therapy with a new cardiotonic agent, WIN 47203; drug-dependent improvement in cardiac performance and progression of the underlying disease. J Am Coll Cardiol 1983; 2: 327–31.
26. Simonton CA, Chatterjee K, Cody RJ, et al. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 1985; 6: 453–9.
27. Timmis AD, Smyth P, Jewett DE. Milrinone in heart failure: effects on exercise haemodynamics during short term treatment. Br Heart J 1985: 54: 42–7.
28. White HD, Ribeiro JP, Hartley LH, Colucci WS. Immediate effects of milrinone on metabolic and sympathetic responses to exercise in severe congestive heart failure. Am J Cardiol 1985; 56: 93–8.
29. LeJemtel TH, Maskin CS, Mancini D, Sinoway L, Feld H, Chadwick B. Systemic and regional hemodynamic effects of captopril and milrinone administered alone and concomitantly in patients with heart failure. Circulation 1985; 72: 364–9.
30. Likoff MJ, Weber KT, Andrews V, Janicki JS, Wilson H, Rocci ML Jr. Milrinone in the treatment of chronic cardiac failure: a controlled trial. Am Heart J 1985; 110: 1035–42.
31. Patterson JA, Naughton J, Pietras RJ, Gunnar RN. Treadmill exercise in assessment of functional capacity of patients with cardiac disease. Am J Cardiol 1972; 30: 757–62.
32. Borg GAV. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982; 14: 377–81.
33. Morganroth J, Horowitz LN. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984; 53: 89B–94B.
34. Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular proarrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986; 8: 607–15.
35. Morganroth J, Borland M, Chao G. Application of a frequency definition of ventricular proarrhythmia. Am J Cardiol 1987; 59: 97–9.
36. DiBianco R, Shabetai R, Silverman BD, Leier CV, Benotti JR. Oral amrinone for the treatment of chronic congestive heart failure: results of a multicenter randomized double-blind and placebo-controlled withdrawal study. J Am Coll Cardiol 1984; 4: 855–66.
37. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation 1985; 71: 963–71.
38. Kubo SH, Cody RJ, Chatterjee K, Simonton C, Rutman H, Leonard D. Acute dose range study of milrinone in congestive heart failure. Am J Cardiol 1985; 55: 726–30.
39. Arnold SB, Byrd RC, Meister W, et al. Long-term digitalis therapy improves left ventricular function in heart failure. N Engl J Med 1980; 303: 1443–8.
40. Lee DC-S, Johnson RA, Bingham JB, et al. Heart failure in outpatients: a randomized trial of digoxin versus placebo. N Engl J Med 1982; 306: 699–705.
41. Dobbs SM, Kenyon WI, Dobbs RJ. Maintenance digoxin after an episode of heart failure: placebo-controlled trial in outpatients. Br Med J 1977; 1: 749–52.
42. Captopril-Digoxin Multicenter Research Group. Comparative effects of therapy with captopril and digoxin in patients with mild to moderate heart failure. JAMA 1988; 259: 539–44.
43. Gheorghiade M, Beller GA. Effects of discontinuing maintenance digoxin therapy in patients with ischemic heart disease and congestive heart failure in sinus rhythm. Am J Cardiol 1983; 51: 1243–50.
44. McHaffie D, Purcell H, Mitchell-Heggs P, Guz A. The clinical value of digoxin in patients with heart failure and sinus rhythm. Q J Med 1978; 47: 401–19.
45. Harris A, Lemp B, Silver P. The effect of ouabain pretreatment on relaxation induced by milrinone and other vasodilators in guinea pig aortic preparations. Report no. 86–67. Rensselaer, N.Y.: Sterling-Winthrop Research Institute, 1987.
46. Ribner HS, Plucinski DA, Hsieh AM, et al. Acute effects of digoxin on total systemic vascular resistance in congestive heart failure due to dilated cardiomyopathy: a hemodynamic-hormonal study. Am J Cardiol 1985; 56: 896–904.
47. Packer M. Sudden unexpected death in patients with congestive heart failure: a second frontier. Circulation 1985; 72: 681–5.
48. Ludmer PL, Baim DS, Antman EM, et al. Effect of milrinone on complex ventricular arrhythmias in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987; 59: 1351–5.
49. Goldstein RA, Geraci SA, Gray EL, Rinkenberger RL, Dougherty AH, Naccarelli GV. Electrophysiologic effects of milrinone in patients with congestive heart failure. Am J Cardiol 1986; 57: 624–8.
50. Anderson JL, Askins JC, Gilbert EM, Menlove RL, Lutz JR. Occurrence of ventricular arrhythmias in patients receiving acute and chronic infusions of milrinone. Am Heart J 1986; 111: 466–74.
51. Holmes JR, Kubo SH, Cody RJ, Kligfield P. Milrinone in congestive heart failure: observations on ambulatory ventricular arrhythmias. Am Heart J 1985; 110: 800–6.